Scinai Immunotherapeutics Ltd. (SCNI)
NASDAQ: SCNI · Real-Time Price · USD
0.8200
-0.0279 (-3.29%)
Jan 22, 2026, 4:00 PM EST - Market closed
Scinai Immunotherapeutics Revenue
Scinai Immunotherapeutics had revenue of $386.50K in the quarter ending June 30, 2025, with 36.09% growth. This brings the company's revenue in the last twelve months to $1.15M, up 303.87% year-over-year. In the year 2024, Scinai Immunotherapeutics had annual revenue of $658.00K.
Revenue (ttm)
$1.15M
Revenue Growth
+303.87%
P/S Ratio
0.94
Revenue / Employee
$37,000
Employees
31
Market Cap
2.84M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 658.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jaguar Health | 11.79M |
| Ensysce Biosciences | 4.49M |
| Onconetix | 1.22M |
| HCW Biologics | 422.03K |
| Cardio Diagnostics Holdings | 15.78K |
| Azitra | 7.50K |
| Aditxt | 5.95K |
SCNI News
- 15 days ago - Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL - PRNewsWire
- 7 weeks ago - Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances - PRNewsWire
- 3 months ago - Scinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities - PRNewsWire
- 5 months ago - Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet - PRNewsWire
- 6 months ago - Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN - PRNewsWire
- 8 months ago - Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025 - PRNewsWire
- 8 months ago - Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l. - PRNewsWire
- 8 months ago - Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn - PRNewsWire